Corpus Intelligence IC Memo — MCLEOD HEALTH CHERAW 2026-04-26 03:50 UTC
IC Memo — MCLEOD HEALTH CHERAW
Investment Committee Memorandum | SC | 46 beds | Grade C | EBITDA uplift $4.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

MCLEOD HEALTH CHERAW

CCN 420107 | CHESTERFIELD, SC | 46 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

MCLEOD HEALTH CHERAW is a 46-bed suburban community hospital in CHESTERFIELD, SC with $54.7M in net patient revenue and a 1.1% operating margin. The hospital serves a payer mix of 35.4% Medicare, 6.6% Medicaid, and 58.0% commercial.

Thesis: Turnaround. Our ML models identify $4.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 1.1% to 8.5% (+736bps).

Net Revenue HCRIS$54.7M
Current EBITDA COMPUTED$613K
Operating Margin COMPUTED1.1%
Occupancy HCRIS49.7%
Revenue / Bed COMPUTED$1.2M
Net-to-Gross HCRIS21.3%
Distress Probability ML48.0%

2. Market Context & Competitive Position

85
SC Hospitals
1.3%
State Median Margin
42
Comparable Hospitals

SC has 85 Medicare-certified hospitals with a median operating margin of 1.3%. The target's margin of 1.1% places it below the state median. Among 42 size-comparable peers (23-92 beds), the median margin is 3.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (23-92), prioritizing same-state peers. 42 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MCLEOD HEALTH CHERAW (Target)SC46$54.7M1.1%
PH PATEWOOD HOSPITALSC64$229.8M38.0%
GEORGETOWN MEMORIAL HOSPITALSC68$168.0M-4.6%
PH GREER MEMORIAL HOSPITALSC66$161.3M31.3%
PH BAPTIST PARKRIDGE HOSPITALSC78$159.8M18.1%
PELHAM MEDICAL CENTERSC48$137.2M17.1%
MUSC HEALTH LANCASTER MEDICAL SC78$128.2M-10.4%
PH HILLCREST HOSPITALSC43$123.6M30.8%
ROPER ST. FRANCIS HOSPITAL-BERSC46$119.0M13.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $4.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.1M+210bp18mo
Cost to Collect4.5%2.5%$1.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.1M+198bp12mo
A/R Days Reduction5200.0%3800.0%$666K+122bp9mo
Clean Claim Rate88.0%96.0%$35K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.1M
Cost to Collect
$1.1M
Denial Rate Reduction
$1.1M
A/R Days Reduction
$666K
Clean Claim Rate
$35K
Total EBITDA Uplift$4.0M
Current EBITDA$613K
+ RCM Uplift+$4.0M
Pro Forma EBITDA$4.6M
Current Margin1.1%
Pro Forma Margin8.5%
WC Released (1x)$2.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$944K$44.3M46.98x116.0%
Base (11x exit)10.0x11.0x$944K$49.1M52.01x120.4%
Bull Case9.0x11.0x$849K$62.7M73.80x136.4%
Bull (12x exit)9.0x12.0x$849K$68.6M80.80x140.7%
Bear Case11.0x10.0x$1.0M$23.9M23.01x87.2%
Bear (11x exit)11.0x11.0x$1.0M$26.6M25.64x91.3%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 42 hospitals with 23-92 beds
  • Same-state prioritization (n=43)
  • Comp margins: P25=-11.9% / P50=3.5% / P75=16.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.